Table 1 |
|||
|
Patients baseline characteristics and BMR, RMR and TEE at baseline 5 days and in the community respectively [mean (SD)] |
|||
|
Variable |
Baseline (n-55) |
Day 5 (n = 32) |
Six weeks in the community (n = 17) |
|
|
|||
|
Age |
76 (9) |
||
|
Gender, female (%) |
8 (40%) |
||
|
Chronic disease/patient |
1.5 |
||
|
Drug/patient+ |
2.1 |
2.1 |
|
|
Body weight (kg) |
70 (13) |
72 (12) |
|
|
BMI (kg/m2) |
26.3 (5.5) |
26.4 (5.5) |
|
|
MUAC (cm) |
29.3 (2.9) |
29.7 (1.9) |
|
|
TSF (mm) |
19 (7.8) |
16.3 (4.4) |
|
|
Thyroid stimulating hormone (normal 0.38–4.7 mμ/L) |
1.6 (0.75) |
3.3 (6.9) |
|
|
C-reactive proteins * (normal <6 mg/L) |
22 (28) |
12 (18) |
5 (7) |
|
Energy Expenditure [BMR] * (Kcal/day) |
1403 (346) |
1317 (446) |
1159 (445) |
|
|
|||
|
* P value for difference between hospital and community values < 0.05 + Diuretics, ACE inhibitors, β-blockers, Calcium channel blockers, statins, aspirin warfarin, clopidogrel, analgesics, benzidiazepines, antidepressants and oral hyopglycaemics |
|||
|
Gariballa and Forster Nutrition Journal 2006 5:9 doi:10.1186/1475-2891-5-9 |
|||
